iRegene Therapeutics (Chengdu) Co., Ltd. ("iRegene" or the "Company"), a biotechnology company pioneering chemically induced allogeneic cell therapy, announced on September 4th the successful completion of its Series B+ financing round, co-led by Northern Light Venture Capital, Chuangjing Capital, and OneHealth Haihe Capital, along with participation from other investors. In August 2025, NouvNeu001 received Fast Track Designation (FTD) from the U.S. FDA, making it the world's first allogeneic iPSC-derived cell therapy for Parkinson's disease to achieve this milestone.

This round builds on a series of sizable financings completed in recent months, bringing iRegene's total funding to over RMB 300 million (~USD 40M). It makes the largest single financing in China's iPSC sector in recent years, highlighting the strong confidence of investor in iRegene's leadership position and long-term strategic vision.

The proceeds will be used to accelerate iRegene's global clinical development of NouvNeu001 for Parkinson's disease (PD), and NouvSight001 for retinal degenerative diseases, while also strengthening early-stage R&D, expanding clinical and operational teams, and advancing iRegene's manufacturing capabilities.